- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INMOLECULE NANOTECH Aktie jetzt für 0€ handeln | |||||
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 26.09.2025 | 64 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.09.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.09.2025
Aktien
1 SE0023135298 NOBA Bank Group AB
2... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 12,580 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| MBX BIOSCIENCES | 17,330 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen | |
| 89BIO | 14,700 | 0,00 % | Roche To Buy 89bio For Up To $3.5 Billion | ||
| BEAM THERAPEUTICS | 23,090 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,520 | 0,00 % | Apogee Therapeutics stock initiated at Outperform by RBC Capital | ||
| MINERALYS THERAPEUTICS | 38,510 | -1,10 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 27,040 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 56,38 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| SCISPARC | 6,130 | 0,00 % | SciSparc Ltd. - 6-K, Report of foreign issuer | ||
| PEPGEN | 5,825 | 0,00 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 13,290 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| ARVINAS | 7,750 | 0,00 % | Arvinas stock downgraded by BofA as Pfizer partnership shifts | ||
| IMMUNEERING | 8,000 | 0,00 % | Mizuho bestätigt Outperform-Rating für Immuneering nach positiven Studiendaten | ||
| MAZE THERAPEUTICS | 26,350 | 0,00 % | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | ||
| EDGEWISE THERAPEUTICS | 14,885 | 0,00 % | Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating |
Das Unternehmen INMOLECULE NANOTECH SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INMOLECULE NANOTECH SA finden Sie auf Wallstreet Online.